Get the Stockscreener App
0.5351
2.90%
0.0151
After Hours:
.51
-0.0251
-4.69%
Ensysce Biosciences Inc stock is traded at $0.5351, with a volume of 105.27K.
It is up +2.90% in the last 24 hours and up +31.47% over the past month.
Ensysce Biosciences Inc is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. The company is developing a new class of powerful, opioids that prevent both drug abuse and overdoses. Its products are anticipated to provide safer options to treat severe pain and assist in preventing deaths caused by opioid abuse, reducing human and economic costs. The company's current development pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, theTrypsin Activated Abuse Protection, or the TAAP platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant, or the MPAR platform. The Company currently operates in one business segment, which is pharmaceuticals.
See More
Previous Close:
$0.52
Open:
$0.5174
24h Volume:
105.27K
Relative Volume:
0.02
Market Cap:
$4.96M
Revenue:
$5.07M
Net Income/Loss:
$-10.18M
P/E Ratio:
-0.1269
EPS:
-4.2178
Net Cash Flow:
$-7.93M
1W Performance:
+8.10%
1M Performance:
+31.47%
6M Performance:
-78.34%
1Y Performance:
-76.11%
1-Day Range:
$0.5001
$0.539
1-Week Range:
$0.4546
$0.60
52-Week Range:
$0.3144
$4.85
Ensysce Biosciences Inc Stock (ENSC) Company Profile
Name
Ensysce Biosciences Inc
Sector
Industry
Phone
(858) 263-4196
Address
7946 IVANHOE AVENUE, LA JOLLA
Compare ENSC vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ENSC
Ensysce Biosciences Inc
|
0.5351 | 4.82M | 5.07M | -10.18M | -7.93M | -4.2178 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Ensysce Biosciences Inc Stock (ENSC) Latest News
Price Action: Will Ensysce Biosciences Inc benefit from geopolitical trendsTrade Volume Summary & Weekly High Potential Alerts - baoquankhu1.vn
Bull Run: Is Ensysce Biosciences Inc subject to activist investor interest2026 Dividend Review & Free Reliable Trade Execution Plans - baoquankhu1.vn
ENSC Should I Buy - Intellectia AI
Ensysce Biosciences (NASDAQ: ENSC) registers 20.3M resale shares - Stock Titan
Ensysce Biosciences Secures $2 Million Second Tranche Financing to Advance Abuse-Resistant Pain Therapies - Minichart
Ensysce Biosciences Secures $2 Million Private Financing - TipRanks
Ensysce Biosciences (NASDAQ: ENSC) closes $2M preferred and warrant deal - Stock Titan
Ensysce Raises $2 Million in Private Placement of Series B Preferred and Warrants - TradingView — Track All Markets
Ensysce Biosciences closes $2M convertible preferred financing By Investing.com - Investing.com South Africa
Ensysce Biosciences Secures Second Financing to Advance Pain Programs - National Today
Ensysce Biosciences closes $2M convertible preferred financing - Investing.com
Pain drug developer pulls another $2M for overdose-resistant treatments - Stock Titan
Ensysce Biosciences Secures Second Financing From 2025 Agreement to Advance Breakthrough Pain Programs - The Globe and Mail
Aug Swings: Does Ensysce Biosciences Inc meet Warren Buffetts criteria2026 Patterns & Reliable Intraday Trade Alerts - baoquankhu1.vn
Stop Loss: Whats the RSI of PETWW stock2026 Sector Review & Real-Time Volume Triggers - baoquankhu1.vn
Ensysce Biosciences, Inc. Announces Director Resignation in April 2026 Form 8-K Filing - Minichart
Ensysce Biosciences director Curtis Rosebraugh resigns from board By Investing.com - Investing.com India
Ensysce Biosciences director Curtis Rosebraugh resigns from board - Investing.com
Ensysce Biosciences Announces Board Member Curtis Rosebraugh Resignation - TipRanks
Board member Curtis Rosebraugh exits Ensysce Biosciences (NASDAQ: ENSC) - Stock Titan
ENSC SEC FilingsEnsysce Biosciences Inc 10-K, 10-Q, 8-K Forms - Stock Titan
ENSC Stock Price, Quote & Chart | ENSYSCE BIOSCIENCES INC (NASDAQ:ENSC) - ChartMill
Ensysce Biosciences, Inc. — Business Overview, Risk Factors, Regulatory Approvals, and Intellectual Property Challenges 64 - Minichart
8-K: Ensysce Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results - Moomoo
Ensysce Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results - bitget.com
Smart Money: Will Ensysce Biosciences Inc benefit from geopolitical trendsWeekly Market Summary & Growth Oriented Trading Recommendations - baoquankhu1.vn
Ensysce Biosciences (NASDAQ: ENSC) outlines abuse-resistant opioid pipeline - Stock Titan
ENSC: Net loss widened to $10.2 million in 2025; ongoing operations depend on new capital raises - TradingView — Track All Markets
Ensysce Biosciences Reports Q4 and Full Year 2025 Results - National Today
Ensysce (NASDAQ: ENSC) advances PF614 programs as 2025 net loss hits $10.2M - Stock Titan
Ensysce Biosciences Q4 net loss narrows to $2.8 mln - TradingView
Ensysce pushes abuse-deterrent opioid into late-stage testing - Stock Titan
Ensysce Biosciences (NASDAQ: ENSC) director quits after opposing retention deals - stocktitan.net
Revenue Check: Does Ensysce Biosciences Inc meet Warren Buffetts criteria2026 Highlights & Low Risk High Reward Ideas - baoquankhu1.vn
Weekly Trades: Is Ensysce Biosciences Inc a turnaround story2026 Snapshot & Fast Exit and Entry Trade Guides - baoquankhu1.vn
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
Ensysce Biosciences Files Certificate of Correction for Series B Preferred Stock with Delaware Secretary of State - Minichart
Ensysce Biosciences files correction to Series B preferred stock designation By Investing.com - Investing.com South Africa
Ensysce Biosciences Corrects Series B Preferred Stock Designation - TipRanks
Ensysce Biosciences files correction to Series B preferred stock designation - Investing.com
Ensysce Biosciences (ENSC) files correction to Series B preferred stock - Stock Titan
If You Invested $1,000 in Ensysce Biosciences Inc (ENSC) - Stock Titan
Earnings Recap: Is Travere Therapeutics Inc stock heavily shorted2026 Technical Patterns & Risk Adjusted Buy/Sell Alerts - baoquankhu1.vn
12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga
Risk Analysis: Is Ensysce Biosciences Inc being accumulated by smart money2026 Setups & Daily Profit Focused Screening - baoquankhu1.vn
Ensysce Biosciences Inc expected to post a loss of $1.26 a shareEarnings Preview - TradingView
ENSC Earnings History & Surprises | EPS & Revenue Results | ENSYSCE BIOSCIENCES INC (NASDAQ:ENSC) - ChartMill
Market Fear: Will Ensysce Biosciences Inc benefit from geopolitical trendsJuly 2025 Setups & Smart Swing Trading Alerts - baoquankhu1.vn
Ensysce Biosciences Initiates Live "Ask Me Anything" (AMA) Session Highlighting Growth and Future Pl - PharmiWeb.com
CEO takes live questions on Ensysce PF614 pain-drug plans - Stock Titan
Ensysce publishes phase 1 data on overdose-limiting opioid tech By Investing.com - Investing.com Australia
Ensysce Biosciences Inc Stock (ENSC) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.69%
0.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):